The problem
The most regulated industry on earth still ships its most critical information on paper — a document that cannot be updated, cannot be verified, and is out of date the day the regulator approves a change.
The platform
The Product Trust Platform is the operating layer for product information: one governed source of truth, verified at every step, live behind every QR code in every market the moment a change is approved. Three products run on it:
Structured ePI authoring, version control and approval workflows, with a blockchain-verified audit trail and same-day propagation to every market and language.
Inventory observability across trading partners, early shortage and disruption signals, and regulator-ready reporting from live operational data.
The current leaflet in the patient's language from one scan, governed microsites and programmes, with consent captured and auditable on every interaction.
What changes for your organisation
Shortage signals days early, stock visibility across partners, label-change write-offs eliminated.
One approved truth in every market; safety variations live at points of care the day they're approved; the audit trail already open at inspection.
Every scan becomes an owned, consented touchpoint with adherence signals you can put in a quarterly review.
The industry business-case model projects >£5M operating-cost reduction within five years and a 0.1% revenue uplift for a top-47-markets portfolio, with Net Zero packaging targets enabled for 75%+ of packs by 2030.**
Deployment & pricing: digital product information from CHF 2,250 per leaflet per year (CORE, shared SaaS) · CHF 14,999 per month (SOLO, dedicated SaaS) · CHF 19,999 per month (EDGE, on-premises). Conversion, hosting, validation pack and support included; portfolio terms covered in the briefing.
Why now
- 2025EMA ePI pilot completes — first electronic leaflets live; Switzerland permits paperless for HCP-administered products (Dec)
- 2026National e-leaflet programmes expand across marketsYou are here
- 2027GS1 Sunrise — 2D barcodes scanned at the point of sale
- 2028EU pharma reform — ePI written into legislation
- 2030Digital becomes the default; paper the fallback
Connecting takes months, not weeks. Teams that start now meet every milestone on this line.
Why the Association
The platform is hosted by the PharmaLedger Association, a Swiss not-for-profit steered by the companies that run on it — grown from 29 founding research partners to 32+ members today. Neutral by legal structure: not venture-backed, not for sale, and incapable of pricing the network against its members. Standards-native (GS1 Digital Link, EMA ePI, FHIR) with verified audit trails and qualified infrastructure designed for regulatory scrutiny. The 2025 replatform completed with zero unplanned customer departures and zero-downtime migration.
Founding research partners (EU IMI programme, 2019–2022): AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck KGaA, Novartis, Novo Nordisk, Pfizer, Roche, UCB — 29 partners across 10 EU member states, with EU Commission and EFPIA endorsement through Horizon 2020.
* Benchmark ranges from industry labelling-change cost models; the full model is shared in the briefing.
** Indicative modelling from the industry business-case framework (2022); validated against your portfolio in the briefing. Detailed production metrics — MAHs live, markets served, patient interactions — are shared under NDA.